Copyright
©The Author(s) 2022.
World J Gastrointest Endosc. Oct 16, 2022; 14(10): 597-607
Published online Oct 16, 2022. doi: 10.4253/wjge.v14.i10.597
Published online Oct 16, 2022. doi: 10.4253/wjge.v14.i10.597
Table 1 Data summary and comparison between patients with and without gastric intestinal metaplasia
| Level | Baseline no GIM | ||||
| Overall | No GIM | GIM | P value | ||
| 579 | 441 | 138 | |||
| Follow-up days [median (IQR)] | 885.0 (257.5, 1901.5) | 857.0 (259.0, 1834.0) | 1087.0 (260.5, 2307.3) | 0.247 | |
| Age baseline [median (IQR)] | 58.0 (49.0, 67.8) | 56.0 (46.8, 65.0) | 64.00 (54.0, 72.0) | < 0.001 | |
| Sex (%) | Male | 227 (39.3) | 166 (37.7) | 61 (44.2) | 0.208 |
| Female | 351 (60.7) | 274 (62.3) | 77 (55.8) | ||
| Ethnicity/Race (%) | Caucasian | 85 (15.9) | 73 (18.1) | 12 ( 9.3) | 0.032 |
| AA | 381 (71.5) | 287 (71.0) | 94 (72.9) | ||
| Hispanic | 18 ( 3.4) | 11 ( 2.7) | 7 ( 5.4) | ||
| Other | 49 ( 9.2) | 33 ( 8.2) | 16 (12.4) | ||
| Obesity (%) | BMI < 30 | 261 (56.7) | 191 (53.5) | 70 (68.0) | 0.013 |
| BMI > 30 | 199 (43.3) | 166 (46.5) | 33 (32.0) | ||
| Smoking status (%) | Never | 269 (54.8) | 207 (55.3) | 62 (53.0) | 0.198 |
| Previous | 119 (24.2) | 84 (22.5) | 35 (29.9) | ||
| Current | 103 (21.0) | 83 (22.2) | 20 (17.1) | ||
| Biopsy site (%) | ≤ 2 | 227 (39.2) | 190 (43.1) | 37 (26.8) | 0.001 |
| > 3 | 352 (60.8) | 251 (56.9) | 101 (73.2) | ||
| H. pylori at Baseline (%) | No | 499 (86.2) | 382 (86.6) | 117 (84.8) | 0.686 |
| Yes | 80 (13.8) | 59 (13.4) | 21 (15.2) | ||
| H. pylori at follow-up (%) | No | 536 (92.6) | 413 (93.7) | 123 (89.1) | 0.114 |
| Yes | 43 ( 7.4) | 28 ( 6.3) | 15 (10.9) | ||
| n | 80 | 59 | 21 | ||
| H. pylori at follow up with positive Baseline (%) | No | 65 (81.2) | 48 (81.4) | 17 (81.0) | 1 |
| Yes | 15 (18.8) | 11 (18.6) | 4 (19.0) | ||
| Gastritis (%) | No | 209 (36.1) | 180 (40.8) | 29 (21.0) | < 0.001 |
| Yes | 370 (63.9) | 261 (59.2) | 109 (79.0) | ||
| Ulcer (%) | No | 534 (92.2) | 408 (92.5) | 126 (91.3) | 0.778 |
| Yes | 45 ( 7.8) | 33 ( 7.5) | 12 ( 8.7) | ||
| 81 mg Aspirin Use at Baseline (%) | No | 450 (77.7) | 347 (78.7) | 103 (74.6) | 0.379 |
| Yes | 129 (22.3) | 94 (21.3) | 35 (25.4) | ||
| 81 mg Aspirin use at follow up (%) | No | 453 (78.2) | 359 (81.4) | 94 (68.1) | 0.001 |
| Yes | 126 (21.8) | 82 (18.6) | 44 (31.9) | ||
| PPI usage at baseline (%) | No | 392 (67.7) | 285 (64.6) | 107 (77.5) | 0.006 |
| Yes | 187 (32.3) | 156 (35.4) | 31 (22.5) | ||
| PPI usage at follow up (%) | No | 318 (54.9) | 233 (52.8) | 85 (61.6) | 0.088 |
| Yes | 261 (45.1) | 208 (47.2) | 53 (38.4) | ||
| Blood type (%) | A | 72 (31.2) | 47 (28.7) | 25 (37.3) | 0.317 |
| B | 42 (18.2) | 28 (17.1) | 14 (20.9) | ||
| O | 109 (47.2) | 82 (50.0) | 27 (40.3) | ||
| AB | 8 ( 3.5) | 7 ( 4.3) | 1 ( 1.5) | ||
| Hemoglobin [median (IQR)] | 11.2 (9.2, 12.8) | 11.5 (9.5, 13.0) | 10.5 (9.0, 12.2) | 0.075 | |
| Hemoglobin Baseline [median (IQR)] | 10.8 (9.2, 12.8) | 11.8 (9.7, 13.1) | 9.60 (8.40, 11.00) | < 0.001 | |
- Citation: Ahmad AI, Lee A, Caplan C, Wikholm C, Pothoulakis I, Almothafer Z, Raval N, Marshall S, Mishra A, Hodgins N, Kang IG, Chang RK, Dailey Z, Daneshmand A, Kapadia A, Oh JH, Rodriguez B, Sehgal A, Sweeney M, Swisher CB, Childers DF, O'Connor C, Sequeira LM, Cho W. Gastric intestinal metaplasia development in African American predominant United States population. World J Gastrointest Endosc 2022; 14(10): 597-607
- URL: https://www.wjgnet.com/1948-5190/full/v14/i10/597.htm
- DOI: https://dx.doi.org/10.4253/wjge.v14.i10.597